A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0
暂无分享,去创建一个
[1] J. B. Gregg,et al. DEPARTMENT OF HEALTH. , 1910, California state journal of medicine.
[2] P. Stattin,et al. Human Papillomavirus 16, 18, and 33 Infections and Risk of Prostate Cancer: A Nordic Nested Case-Control Study , 2005, Cancer Epidemiology Biomarkers & Prevention.
[3] Jie Lin,et al. Urinary tract diseases and bladder cancer risk: a case–control study , 2007, Cancer Causes & Control.
[4] D. English,et al. Plasma concentration of Propionibacterium acnes antibodies and prostate cancer risk: results from an Australian population-based case–control study , 2010, British Journal of Cancer.
[5] P. Stattin,et al. Chlamydial Antibodies and Risk of Prostate Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.
[6] W. Willett,et al. Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.
[7] Jennifer R. Rider,et al. Frequency and typing of Propionibacterium acnes in prostate tissue obtained from men with and without prostate cancer , 2016, Infectious Agents and Cancer.
[8] P. Stattin,et al. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base—a refined prostate cancer trajectory , 2015, International journal of epidemiology.
[9] E. Negri,et al. Genital and urinary tract diseases and prostate cancer risk , 2006, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[10] W. Stamm. Scientific and clinical challenges in the management of urinary tract infections. , 2002, The American journal of medicine.
[11] J. Vijayakumar,et al. Correlation of Prostate Gland Size and Uroflowmetry in Patients with Lower Urinary Tract Symptoms. , 2017, Journal of clinical and diagnostic research : JCDR.
[12] J. McNeal,et al. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? , 2005, The Journal of urology.
[13] A. L. Conte,et al. Features of uropathogenic Escherichia coli able to invade a prostate cell line. , 2016, The new microbiologica.
[14] M. Nowicki,et al. New markers of urinary tract infection. , 2017, Clinica chimica acta; international journal of clinical chemistry.
[15] S. Miyamoto,et al. Chemopreventive effects of a low-side-effect antibiotic drug, erythromycin, on mouse intestinal tumors , 2017, Journal of clinical biochemistry and nutrition.
[16] P. Stattin,et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. , 2013, International journal of epidemiology.
[17] F. Saad,et al. Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case–control study , 2016, World Journal of Urology.
[18] Cheng-Li Lin,et al. Lower Urinary Tract Infection and Subsequent Risk of Prostate Cancer: A Nationwide Population-Based Cohort Study , 2017, PloS one.
[19] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[20] A. D. De Marzo,et al. Prostate cancer and inflammation: the evidence , 2012, Histopathology.